What were the specific terms and dilution impact of the September 11, 2025, $26.9 million public offering?

Lucid Diagnostics Inc. (US:LUCD) successfully closed a public offering on September 11, 2025, raising approximately $26.9 million in net proceeds.

Here are the specific terms of the offering:

• Shares Issued: The company issued a total of 28,750,000 shares of common stock. This figure includes the full exercise of the underwriters' option to purchase an additional 3,750,000 shares.
• Offering Price: Each share was sold at a public offering price of $1.00.
• Gross Proceeds: The gross proceeds from the offering were approximately $28.75 million (28,750,000 shares * $1.00/share).
• Net Proceeds: After deducting underwriting discounts, commissions, and other estimated offering expenses, the company received approximately $26.9 million.
• Use of Proceeds: Lucid Diagnostics stated its intention to use the net proceeds for working capital and general corporate purposes.
• Underwriters: Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners, with Maxim Group LLC serving as co-manager.

The issuance of 28,750,000 new shares of common stock in this offering represents a direct dilutive event for existing shareholders, increasing the total number of outstanding shares. Without the exact number of shares outstanding immediately prior to this offering, the precise percentage of dilution cannot be calculated, but the increase in share count directly impacts each existing share's proportional ownership.

Calculate the percentage dilution impact of the 28,750,000 newly issued shares on existing Lucid Diagnostics Inc. shareholders.